{
    "name": "latanoprost",
    "comment": "Rx",
    "other_names": [
        "Xalatan",
        "Xelpros",
        "Iyuzeh"
    ],
    "classes": [
        "Antiglaucoma",
        "Prostaglandin Agonists"
    ],
    "source": "https://reference.medscape.com/drug/xalatan-latanoprost-343606",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women",
            "Only use during pregnancy if potential benefits justifies potential risks to the fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproduction studies performed in rats and rabbits. In rabbits, an incidence of 4 of 16 dams had no viable fetuses at a dose that was ~80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was ~15 times the maximum human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not known whether this drug or its metabolites are excreted in human milk; because many drugs are excreted in human milk, exercise caution drug is administered to a nursing woman",
            "Consider developmental and health benefits of breastfeeding along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from therapy"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to latanoprost, benzalkonium chloride, or other components of product"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Macular edema, including cystoid macular edema, reported; Caution caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema",
                "Caution in active intraocular inflammation (eg, iritis/uveitis); generally not for use in patients with active intraocular inflammation; may exacerbate inflammation",
                "Reactivation of herpes simplex keratitis reported; administer with caution in patients with a history of herpetic keratitis; avoid in cases of active herpes simplex keratitis because inflammation may be exacerbated",
                "Take contact lenses out when applying, reinsert at least 15 min later",
                "Bacterial keratitis may result from inadvertent contamination of multidose ophthalmic solutions",
                "Gradual changes in eyelashes and vellus hair (eg, increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth of eyelashes) may occur; changes are usually reversible upon discontinuation of treatment",
                "May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes; after discontinuation, pigmentation of the iris is likely to be permanent, while pigmentation of periorbital tissue and eyelash changes may be reversible in some patients; inform patients of possibility of increased pigmentation; continue treatment in patients who develop noticeably increased iris pigmentation and examine them regularly"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "bimatoprost",
            "description": {
                "common": "latanoprost, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "latanoprostene bunod ophthalmic",
            "description": {
                "common": "latanoprost, latanoprostene bunod ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tafluprost",
            "description": {
                "common": "latanoprost, tafluprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "travoprost ophthalmic",
            "description": {
                "common": "latanoprost, travoprost ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "latanoprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "latanoprost, aspirin rectal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromfenac ophthalmic",
            "description": {
                "common": "latanoprost, bromfenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "latanoprost, celecoxib. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "latanoprost, choline magnesium trisalicylate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "latanoprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac ophthalmic",
            "description": {
                "common": "latanoprost, diclofenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "latanoprost, diflunisal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "latanoprost, etodolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "latanoprost, fenoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "latanoprost, flurbiprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen ophthalmic",
            "description": {
                "common": "latanoprost, flurbiprofen ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "latanoprost, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "latanoprost, ibuprofen IV. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen/famotidine",
            "description": {
                "common": "latanoprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "latanoprost, indomethacin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "latanoprost, ketoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "latanoprost, ketorolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "latanoprost, ketorolac intranasal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac ophthalmic",
            "description": {
                "common": "latanoprost, ketorolac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "latanoprost, meclofenamate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "latanoprost, mefenamic acid. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "latanoprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "latanoprost, nabumetone. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "latanoprost, naproxen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nepafenac ophthalmic",
            "description": {
                "common": "latanoprost, nepafenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "latanoprost, oxaprozin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "latanoprost, piroxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "latanoprost, salsalate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "latanoprost, sulindac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "latanoprost, tolmetin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Increase in brown pigmentation of the iris",
            "percent": "15.5"
        },
        {
            "name": "Blurred vision",
            "percent": "5-15"
        },
        {
            "name": "Burning and stinging",
            "percent": "5-15"
        },
        {
            "name": "Foreign body sensation",
            "percent": "5-15"
        },
        {
            "name": "Itching",
            "percent": "5-15"
        },
        {
            "name": "Punctate epithelial keratopathy",
            "percent": "5-15"
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": "5-15"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "4"
        },
        {
            "name": "cold",
            "percent": "1-4"
        },
        {
            "name": "flu",
            "percent": "1-4"
        },
        {
            "name": "Dry eye",
            "percent": "1-4"
        },
        {
            "name": "Excessive tearing",
            "percent": "1-4"
        },
        {
            "name": "Eye pain",
            "percent": "1-4"
        },
        {
            "name": "Lid crusting",
            "percent": "1-4"
        },
        {
            "name": "Lid edema",
            "percent": "1-4"
        },
        {
            "name": "Lid erythema",
            "percent": "1-4"
        },
        {
            "name": "Lid discomfort",
            "percent": "1-2"
        },
        {
            "name": "pain",
            "percent": "1-2"
        },
        {
            "name": "Photophobia",
            "percent": "1-2"
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "angina pectoris",
            "percent": null
        },
        {
            "name": "Muscle",
            "percent": null
        },
        {
            "name": "joint",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "allergic skin reactions",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Diplopia",
            "percent": null
        },
        {
            "name": "Discharge from the eye",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Retinal artery embolus",
            "percent": null
        },
        {
            "name": "Vitreous hemorrhage from diabetic retinopathy",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eyelash and vellus hair changes of eyelid",
            "percent": null
        },
        {
            "name": "increased length",
            "percent": null
        },
        {
            "name": "thickness",
            "percent": null
        },
        {
            "name": "pigmentation",
            "percent": null
        },
        {
            "name": "and number of eyelashes",
            "percent": null
        },
        {
            "name": "keratitis",
            "percent": null
        },
        {
            "name": "corneal edema and erosions",
            "percent": null
        },
        {
            "name": "intraocular inflammation",
            "percent": null
        },
        {
            "name": "iritis",
            "percent": null
        },
        {
            "name": "uveitis",
            "percent": null
        },
        {
            "name": "macular edema",
            "percent": null
        },
        {
            "name": "including cystoid macular edema",
            "percent": null
        },
        {
            "name": "trichiasis",
            "percent": null
        },
        {
            "name": "periorbital and lid changes resulting in deepening of the eyelid sulcus",
            "percent": null
        },
        {
            "name": "iris cyst",
            "percent": null
        },
        {
            "name": "eyelid skin darkening",
            "percent": null
        },
        {
            "name": "localized skin reaction on the eyelids",
            "percent": null
        },
        {
            "name": "conjunctivitis",
            "percent": null
        },
        {
            "name": "pseudopemphigoid of the ocular conjunctiva",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Angina",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "angina unstable",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        }
    ]
}